Login to Your Account



Other News To Note


Monday, July 9, 2012
• R-Pharm, of Moscow, recently inked a deal with Whitehouse Station, N.J.-based Merck & Co. Inc. for rights to an investigational hepatitis C virus (HCV) once-daily protease inhibitor, narlaprevir. Under the terms, R-Pharm gains the right to develop and commercialize narlaprevir in Russia and the Commonwealth of Independent States in exchange for an undisclosed up-front payment and royalties.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription